The versatile peptides penetrating deep into tissue


Bicycles® are synthetic bicyclic peptides rotationally limited by symmetrical small molecule scaffolds that constrain the molecule into rigid two-loop structures. They can be optimised to have high affinity and exquisite selectivity to difficult-to-drug targets. Bicycles are made stable through optimisation and their low molecular weight delivers favourable pharmacokinetics, enabling deep tissue penetration, high solubility and flexibility in the areas of manufacturing, route of administration and formulation.

Bicycles are being investigated in a number of ways and disease areas, including as cytotoxic targeting agents (Bicycle® Toxin Conjugates, or BTCs) where a tumor-targeting Bicycle is linked to a toxin payload to form a drug conjugate.1 The tumor-targeted Bicycle directs the payload to the specific cell or tissue for release and targeted therapeutic response.

Bicycles can also be joined with each other to form higher order structures such as tandems, trimers, and tetramers, allowing them to engage targets and target classes inaccessible to traditional small molecules or to engage multiple drug targets or cell types simultaneously.

Bicycles are a new modality that have the potential to become part of the next generation of therapeutics, combining specificity, potency, and attractive drug-like properties. In collaboration with Bicycle Therapeutics, we are developing Bicycle-based molecules against a wide range of drug targets in two of our therapy areas, Respiratory & Immunology and Cardiovascular, Renal and Metabolism. 


With the versatility and molecular specificity of bicyclic peptides, our aim is to rapidly investigate drug targets in several indications across our therapeutic areas.

Maria Belvisi SVP and Head of Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D

Join us

If you believe in the power of what science can do, join us in our endeavour to push the boundaries of science to deliver life-changing medicines.


Collaborate with us

We know that however innovative our science, however effective our medicines and delivery, to achieve all we want to achieve, we cannot do it alone.


Veeva ID: Z4-46778
Date of preparation: August 2022